Together our results indicate that dysregulated CARS2/CPERS-dependent supersulfide metabolism in CD4+ T cells can lead to intestinal inflammation, and further suggest the same metabolic pathway as a potential therapeutic target for IBD treatment. This evidence concerns the gene CD4 and inflammatory bowel disease.